differentiated antibiotics

Cempra's Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity

CHAPEL HILL, N.C., April 3, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced the presentation of a late-breaking abstract entitled "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," at 9:15 a.m. EDT, May 6, at Digestive Disease Week (DDW®) 2014 in Room S105A at McCormick Place in Chicago.

 

Cempra to Present Late-Breaker on Solithromycin Reducing Inflammation in an Animal Model for Cancer Chemotherapy-Induced Lung Injury

CHAPEL HILL, N.C., March 27, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycin reduced inflammation in an animal model for inflammatory lung disease at the American Thoracic Society (ATS) 2014 International Conference in San Diego.